DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|rareLife solutions 606 Post Road East #397
Westport, CT 06880
|You are receiving this because you have an account on www.oneAMYLOIDOSISvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
The first team to disable a disease gene directly in a person through an infusion of the genome editor CRISPR reported yesterday that levels of the toxic protein made by the gene dropped as much as 93% for up to 1 year. The researchers hope the long-term reduction means patients in the clinical trial will soon show clear improvement in their nerve symptoms and that these benefits will persist for an extended period.
“It is quite remarkable that this first [intravenous] CRISPR-based gene-editing effort has been so successful,” says gene therapy researcher Terence Flotte of the University of Massachusetts Medical School, who was not involved with the study. “This demonstrates great potential for the power of this platform clinically.”
news & meetingsWith CRISPR Gene Editing, Unique Treatments Begin to Take off for Rare DiseasesIn February last year, Doherty — now a...
news & meetingsIntellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022Intellia Therapeutics, Inc. (NASDAQ:NTLA...
news & meetingsHe Inherited A Devastating Disease. A CRISPR Gene-Editing Breakthrough Stopped ItPatrick Doherty had always been very act...
news & meetingsIntellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CR...Intellia Therapeutics, Inc. and Regenero...
people & placesFroedtert Hospital Cancer CenterFroedtert Hospital Cancer Center gives...
people & placesSuzanne R. Hayman, MDSuzanne R. Hayman is a Consultant in the...
people & placesSafwan Jaradeh, MDDr. Jaradeh is a Professor of Neurology ...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.